| Hannah Munyan Sikes, OD | |
|
1001 N Grand Ave, Tahlequah, OK 74464-7017 | |
| (918) 444-4007 | |
| Not Available |
| Full Name | Hannah Munyan Sikes |
|---|---|
| Gender | Female |
| Speciality | Optometry |
| Experience | 3 Years |
| Location | 1001 N Grand Ave, Tahlequah, Oklahoma |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063092468 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | 3137 (Oklahoma) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Cherokee Nation W W Hastings Indian Hospital | Tahlequah, OK | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Cherokee Nation | 5799698742 | 329 |
News Archive
ZymoGenetics, Inc. today announced the initiation of the second part of a Phase 2 clinical trial with PEG-Interferon lambda (IL-29) and ribavirin in treatment-naïve patients with chronic hepatitis C virus (HCV) infection. ZymoGenetics is developing the investigational compound PEG-Interferon lambda in collaboration with Bristol-Myers Squibb Company.
Enzo Biochem, Inc. today announced that the New York State Department of Health has approved Enzo Clinical Labs' use of the ColonSentry test for providing an assessment of a patient's risk of having colorectal cancer.
An experimental drug to treat Alzheimer's disease has had some promising results in early trials with patients.
NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular diagnostics, today announced the availability of a comprehensive multiplexed assay for the simple and cost-effective analysis of fusion genes linked to leukemia.
› Verified 8 days ago
| Provider Name | Cherokee Nation |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1780692723 PECOS PAC ID: 5799698742 Enrollment ID: O20031106000628 |
News Archive
ZymoGenetics, Inc. today announced the initiation of the second part of a Phase 2 clinical trial with PEG-Interferon lambda (IL-29) and ribavirin in treatment-naïve patients with chronic hepatitis C virus (HCV) infection. ZymoGenetics is developing the investigational compound PEG-Interferon lambda in collaboration with Bristol-Myers Squibb Company.
Enzo Biochem, Inc. today announced that the New York State Department of Health has approved Enzo Clinical Labs' use of the ColonSentry test for providing an assessment of a patient's risk of having colorectal cancer.
An experimental drug to treat Alzheimer's disease has had some promising results in early trials with patients.
NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular diagnostics, today announced the availability of a comprehensive multiplexed assay for the simple and cost-effective analysis of fusion genes linked to leukemia.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Hannah Munyan Sikes, OD 1001 N Grand Ave, Tahlequah, OK 74464-7017 Ph: (918) 444-4007 | Hannah Munyan Sikes, OD 1001 N Grand Ave, Tahlequah, OK 74464-7017 Ph: (918) 444-4007 |
News Archive
ZymoGenetics, Inc. today announced the initiation of the second part of a Phase 2 clinical trial with PEG-Interferon lambda (IL-29) and ribavirin in treatment-naïve patients with chronic hepatitis C virus (HCV) infection. ZymoGenetics is developing the investigational compound PEG-Interferon lambda in collaboration with Bristol-Myers Squibb Company.
Enzo Biochem, Inc. today announced that the New York State Department of Health has approved Enzo Clinical Labs' use of the ColonSentry test for providing an assessment of a patient's risk of having colorectal cancer.
An experimental drug to treat Alzheimer's disease has had some promising results in early trials with patients.
NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular diagnostics, today announced the availability of a comprehensive multiplexed assay for the simple and cost-effective analysis of fusion genes linked to leukemia.
› Verified 8 days ago
Dr. Michele Bither-marshall, OD Optometrist Medicare: Not Enrolled in Medicare Practice Location: 1001 N Grand Ave, Tahlequah, OK 74464 Phone: 918-458-2109 Fax: 918-458-2310 | |
Dr. Rodney Bendure, OD Optometrist Medicare: Not Enrolled in Medicare Practice Location: 1001 N Grand Ave, Tahlequah, OK 74464 Phone: 918-458-2109 Fax: 918-458-2310 | |
Tahlequah Family Vision Clinic Optometrist Medicare: Medicare Enrolled Practice Location: 681 W Choctaw St, Tahlequah, OK 74464 Phone: 918-456-2250 Fax: 918-456-2251 | |
Dr. Megan Jean Chee, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 1001 N Grand Ave, Nsu Oklahoma College Of Optometry, Tahlequah, OK 74464 Phone: 918-444-4031 | |
Dr. Latricia Pack, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 1001 N Grand Ave, Tahlequah, OK 74464 Phone: 918-458-2109 Fax: 918-458-2310 | |
Dr. Laura Lai Ming Chan, OD Optometrist Medicare: Medicare Enrolled Practice Location: 1001 N Grand Ave, Tahlequah, OK 74464 Phone: 918-444-4000 |